Mounjaro and the Billions in Question

On Tuesday, October 13, a room in Dublin will fill with experts who hold a pen that could redraw the map of Irish healthcare. The HSE Drugs Group is convening to debate a single question: should Mounjaro, the weight loss injection from Eli Lilly, be made available to the public at free or reduced cost? It is a decision that balances clinical hope against a price tag estimated at upwards of €2 to €3 billion.

This is not just another drug on a shelf. It is a potential watershed moment for a population where obesity is a leading driver of chronic disease. The stakes are high, the evidence is mounting, and the financial implications are staggering. For the first time, the conversation is not about whether these drugs work, but about who can afford to access them when they need them most.

The Numbers Behind the Debate

The scale of the issue becomes clear when you look at the data. Professor Donal O’Shea, a consultant endocrinologist, has estimated that more than a million people in Ireland are likely to be eligible for this treatment. That is a vast number of individuals who could see their health trajectory change, but it also represents a massive strain on the state budget.

The cost is the elephant in the room. Eli Lilly has engaged with Irish authorities on pricing, but the final figure remains a source of intense scrutiny. The HSE must justify this expenditure not just as a cost, but as an investment in long term health outcomes. It is a complex calculation that goes far beyond the price of a single injection.

More Than Just Weight Loss

What makes this particular drug different from its predecessors is the breadth of its benefits. Prof O’Shea has highlighted that the advantages extend well beyond the scale. There are significant improvements in blood pressure and insulin resistance, which directly reduces the likelihood of developing type 2 diabetes.

The protective effects do not stop there. Emerging evidence suggests a lower risk of cancer development, offering a layer of protection that was previously unimaginable for a weight loss therapy. For patients with Down Syndrome or intellectual disabilities, where obesity is a major driver of dementia, these benefits could be life changing. It is about preserving quality of life and preventing the cascade of chronic conditions that follow.

This broader clinical picture is what the Drugs Group will be weighing. It is not simply a matter of losing kilograms; it is about preventing the downstream costs of untreated metabolic disease. The argument for reimbursement is built on this wider health impact.

The Budgetary Tightrope

The HSE faces a difficult arithmetic problem. Spending billions now to save money later is a concept that is hard to visualise in a yearly budget report. Prof O’Shea notes that you never see the money saved in the health service because the hip that doesn’t get replaced or the diabetes that is not developed simply does not appear in the accounts.

This creates a political and financial challenge. The state must allocate funds for prevention when the savings are invisible and long term. It requires a shift in thinking from reactive treatment to proactive management, a change that is culturally and financially difficult to achieve in a public health system.

A Shift in Access

Currently, access to these medications in Ireland is fragmented. Saxenda is the only GLP-1 therapy reimbursed for weight loss, available for free under the medical card or subsidised under the Drugs Payment Scheme. Ozempic is only available for type 2 diabetes, leaving those with obesity but no diabetes to pay privately, often more than €200 a month.

If Mounjaro is approved, it could bridge this gap. It would provide a weekly injection option that is potentially more convenient and effective for a larger group of patients. The decision could effectively democratise access to a class of drugs that has until now been largely a privilege of the privately insured.

What Comes Next

The meeting on Tuesday is the first step in a process that will take time. The HSE has warned that several meetings may be required before a recommendation is made to senior management. Discussions with the Department of Health on the overall impact on the health budget will be crucial.

In the meantime, the focus remains on the evidence. The Drugs Group will look at the clinical benefits, the cost effectiveness, and the impact on the population. It is a decision that will be watched closely by patients, doctors, and policymakers alike, knowing that the outcome will shape the future of weight management in Ireland.